The research team noted that racial subgroups are underrepresented in clinical trials, a factor that should be addressed in ...

Patients requiring frequent ranibizumab intravitreal injections for various indications as part of their routine clinical care were recruited to partake in this study. The primary goal of the ...

The FDA has set a goal date of Aug. 27, 2025. If approved, the therapy would be branded as Lytenava and be the first ...

The green light comes on the back of the phase 3 ARCHWAY trial which showed that Susvimo was equivalent to monthly Lucentis injections at maintaining vision in patients over 40 weeks, with 98% of ...

Lucentis' main patents are not due to expire ... intervals between dosing - an attractive proposition for patients as injections need to be administered into the eye - but has been affected ...

Bevacizumab may be preferable to ranibizumab in the treatment of retinopathy of prematurity in as far as it is associated with a lower risk of retreatment.

The ranibizumab biosimilar Ongavia exhibited significantly less improvement in visual acuity and retinal thickness compared ...

Prescription Drug User Fee Act (PDUFA) goal date of August 27, 2025 ISELIN, N.J., April 08, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc.

Additionally, while at Ophthotech (later Iveric Bio), he was involved in the early development of Izervay®, a prescription eye injection used to treat geographic atrophy (GA), an advanced form of ...

The NORSE EIGHT non-inferiority study enrolled newly diagnosed wet AMD patients, who were randomly divided equally to receive either 1.25 mg ONS-5010 or 0.5 mg Lucentis (ranibizumab) intravitreal ...

Treatments include focal laser photocoagulation for non–center-involved DME, which reduces vision loss risk by 50% to 70%, and intravitreal anti-vascular endothelial growth factor (VEGF) injections (e ...